Skip to main content
Advertisement

PLOS ONE

  • Publish
    • Submissions
      • Getting Started
      • Submission Guidelines
      • Figures
      • Tables
      • Supporting Information
      • LaTeX
      • What We Publish
      • Preprints
      • Revising Your Manuscript
      • Submit Now
      • Calls for Papers
    • Policies
      • Best Practices in Research Reporting
      • Human Subjects Research
      • Animal Research
      • Competing Interests
      • Disclosure of Funding Sources
      • Licenses and Copyright
      • Data Availability
      • Complementary Research
      • Materials, Software and Code Sharing
      • Ethical Publishing Practice
      • Authorship
      • Corrections, Expressions of Concern, and Retractions
    • Manuscript Review and Publication
      • Criteria for Publication
      • Editorial and Peer Review Process
      • Editor Center
      • Resources for Editors
      • Guidelines for Reviewers
      • Accepted Manuscripts
      • Comments

    Submit Your Manuscript

    Discover a faster, simpler path to publishing in a high-quality journal. PLOS ONE promises fair, rigorous peer review, broad scope, and wide readership – a perfect fit for your research every time.

    Learn More Submit Now

  • About
    • Why Publish with PLOS ONE
    • Journal Information
    • Staff Editors
    • Editorial Board
    • Section Editors
    • Advisory Groups
    • Find and Read Articles
    • Publishing Information
    • Publication Fees
    • Press and Media
    • Contact
  • Browse
  • Search
    advanced search
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody

  • Mark T. Winkler,

    Affiliation Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Ryan T. Bushey,

    Affiliation Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Elizabeth B. Gottlin,

    Affiliation Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Michael J. Campa,

    Affiliation Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Eross S. Guadalupe,

    Affiliation Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Alicia D. Volkheimer,

    Affiliations Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Durham VA Medical Center, Durham, North Carolina, United States of America

    ⨯
  • J. Brice Weinberg,

    Affiliations Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Durham VA Medical Center, Durham, North Carolina, United States of America, Department of Immunology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯
  • Edward F. Patz Jr.

    * E-mail: patz0002@mc.duke.edu

    Affiliations Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America, Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America

    ⨯

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody

  • Mark T. Winkler, 
  • Ryan T. Bushey, 
  • Elizabeth B. Gottlin, 
  • Michael J. Campa, 
  • Eross S. Guadalupe, 
  • Alicia D. Volkheimer, 
  • J. Brice Weinberg, 
  • Edward F. Patz Jr.
PLOS
x
  • Published: June 28, 2017
  • https://doi.org/10.1371/journal.pone.0179841
  • Article
  • Authors
  • Metrics
  • Comments
  • Media Coverage
Download PDF
 
  • Citation
  • XML
Print
  • Print article
  • Reprints
Share
  • RedditReddit
  • FacebookFacebook
  • LinkedInLinkedIn
  • MendeleyMendeley
  • TwitterTwitter
  • EmailEmail
  Check for updates via CrossMark
Advertisement

Subject Areas
?

For more information about PLOS Subject Areas, click here.

We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

  • Cytotoxicity  

    Is the Subject Area "Cytotoxicity" applicable to this article?

    Thanks for your feedback.

  • B cells  

    Is the Subject Area "B cells" applicable to this article?

    Thanks for your feedback.

  • Complement system  

    Is the Subject Area "Complement system" applicable to this article?

    Thanks for your feedback.

  • Flow cytometry  

    Is the Subject Area "Flow cytometry" applicable to this article?

    Thanks for your feedback.

  • Antibody response  

    Is the Subject Area "Antibody response" applicable to this article?

    Thanks for your feedback.

  • Cancer treatment  

    Is the Subject Area "Cancer treatment" applicable to this article?

    Thanks for your feedback.

  • Antibody therapy  

    Is the Subject Area "Antibody therapy" applicable to this article?

    Thanks for your feedback.

  • Monoclonal antibodies  

    Is the Subject Area "Monoclonal antibodies" applicable to this article?

    Thanks for your feedback.

  • Publications
  • PLOS Biology
  • PLOS Medicine
  • PLOS Computational Biology
  • PLOS Genetics
  • PLOS Pathogens
  • PLOS ONE
  • PLOS Neglected Tropical Diseases
  •  
  • PLOS Climate
  • PLOS Digital Health
  • PLOS Global Public Health
  • PLOS Sustainability and Transformation
  • PLOS Water
  • Home
  • Blogs
  • Collections
  • Give feedback
  • LOCKSS
  • Privacy Policy
  • Terms of Use
  • Advertise
  • Media Inquiries
  • Contact

PLOS PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in San Francisco, California, US